After stratifying patients based on tumor mutations, we observed that fibroblast enrichment predicted a poor prognosis, whereas CCL20+ IL1B+ macrophage enrichment indicated significantly prolonged survival in KRAS/TP53 wild-type tumors (Figure 7E; Supplementary Figures 6A–D). The gene discussed is TP53; the disease is neoplasm.